Royalty Report: Drugs, Cancer, Disease – Collection: 371771

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Drugs
  • Cancer
  • Disease
  • Biotechnology
  • Therapeutic
  • Pharmaceuticals
  • Kidneys
  • DNA
  • Diagnostic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 371771

License Grant
Licensor of Switzerland hereby grants to Licensee of Denmark (a) an exclusive, royalty-bearing, sublicensable assignable license under the Licensed Data and Product-Specific Patents and (b) a non-exclusive, royalty-bearing, sublicensable assignable license under the Platform Patents, in the case of (a) and (b) solely to Develop and otherwise Commercialize the Licensed Product in the Field in the Territory and to Manufacture and have Manufactured the Compound for use in a Licensed Product in the Field in the Territory as of the Effective Date.
License Property
Licensor own or control the certain Intellectual Property Rights (as defined below) Covering the Compound (as defined below) and has conducted Phase II Clinical Trials and Phase III Clinical Trials of the Compound for the treatment of gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), breast cancer, and other solid tumors.

Dovitinib is a pan-tyrosine kinase inhibitor targeting fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR) and other receptor tyrosine kinases (RTKs). Dovitinib binds to and inhibits the phosphorylation of type III-V RTKs, such as vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) that promote tumor cell proliferation and survival in certain cancer cells. In addition, this agent also inhibits other members of the RTK superfamily, including fibroblast growth factor receptor 1 and 3, FMS-like tyrosine kinase 3, stem cell factor receptor (c-KIT), and colony stimulating factor receptor 1. This may further lead to a reduction of cellular proliferation and angiogenesis, and an induction of tumor cell apoptosis.

TKI258 is a yellow to orange and/or brownish tinged, nonhygroscopic solid that dissociates into TKI258 free base and lactic acid between 125 to 250oC.

Platform Patents
PCT/US2003/010463

Product-Specific Patents
PCT/US2001/042131
PCT/EP2011/055906
PCT/EP2011/060949
PCT/US2013/023781
PCT/US2003/010463
PCT/US2012/029205

Field of Use
Field of use is for the treatment of Cancer.

IPSCIO Record ID: 4661

License Grant
The parties entered into an exclusive license agreement to develop and commercialize lucitanib on a global basis, excluding China.
License Property
Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 (FGFR1-3), vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR α-ß).
Field of Use
A Phase I/IIa clinical trial of lucitanib was initiated in 2010 and has demonstrated multiple objective responses in FGFR1 gene-amplified breast cancer patients, and objective responses were also observed in patients with tumors often sensitive to VEGFR inhibitors, such as renal cell and thyroid cancer. FGFR amplification is common in a number of tumor types, including breast cancer and squamous non-small cell lung cancer, and we intend to study lucitanib in these cancers as well as other solid tumors exhibiting FGFR pathway activation.

IPSCIO Record ID: 307845

License Grant
Licensee licensed rights to tivozanib. Pursuant to the license agreement, Licensee obtained an exclusive, sublicensable license to develop, manufacture and commercialize tivozanib worldwide except for Asia and the Middle East, where Licensor retained the rights to tivozanib.
License Property
Tivozanib (FOTIVDA®) is a vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor.  Tivozanib, a potent, selective and long half-life inhibitor of all three vascular endothelial growth factor, or VEGF, receptors is designed to optimize VEGF blockade while minimizing off-target toxicities, resulting in demonstrated improved anti-tumor activity, as measured by progression-free survival, or PFS, overall response rate, or ORR, and duration of response, and tolerability, as measured by the need for significantly fewer dose reductions and interruptions due to adverse events, compared to a non-selective VEGFR TKI, sorafenib.

Licensor is a specialty pharmaceutical company engaged in the development and commercialization of prescription medicines for the treatment of unmet therapeutic needs in major western markets.

Field of Use
The field of use is for the treatment of adult patients with advanced renal cell carcinoma (RCC).  

Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport primary urine.

Licensee is a biopharmaceutical company developing and seeking to commercialize the pipeline of product candidates designed to provide a better life for patients with cancer.  Licensee is working to develop and commercialize tivozanib in North America as a treatment for RCC and hepatocellular carcinoma, or HCC, and is studying tivozanib in combination with immune checkpoint inhibitors for the treatment of RCC and HCC in phase 2 trials.

IPSCIO Record ID: 33130

License Grant
The Licensor of Hong Kong and Licensee of China agree to collaborate with respect to the Development of the Product in the Field with the goal of obtaining Regulatory Approval for Products in the Field in the Territory for Manufacturing and Commercialization. Lilly will have exclusive rights to Commercialize the Products in the Field in the Territory.

For the Exclusive License and Right to Sublicense, Licensor grants an exclusive license, including the right to grant sublicenses, under Licensor Patents, Know-How and Regulatory Approvals to Develop, use, import and Commercialize, but, for clarity, not to make or have made Products in the Field in the Territory.

License Property
Licensor is the owner of a molecule HMPL-013 and is developing it for the Chinese market as a pharmaceutical product useful in the treatment of cancer.

Product means any form or dosage of the HMPL-013 molecule or any analogues or derivatives of the HMPL-013 molecule that are claimed by those Licensor Patents that also claim HMPL-013, in each case that exist as of the Effective Date or are discovered or developed by Licensor during the Term of this Agreement.

HMPL-013, named  Fruquintinib, patents and patent applications report compounds related to Fruquintinib and compositions comprising at least one compound, and methods for inhibiting KDR activity and treating angiogenesis–related disorders with such compounds/compositions.
Fruquintinib is a selective inhibitor of the Vascular Endothelial Growth Factor (VEGF) receptor tyrosine kinases.

Combination Products means any combination or Product and one or more additional active pharmaceutical ingredients, for example in a single delivery device such as a pre-filled pen, dual chamber needle or in a fixed dose combination.

Fruquintinib is a highly selective and potent oral inhibitor of the vascular endothelial growth factor receptor, or VEGFR, and consequently we believe it has the potential to be a global best-in-class VEGFR inhibitor for many types of solid tumors. Based on pre-clinical and clinical data to date, fruquintinibs kinase selectivity has been shown to reduce off-target toxicity. This allows for drug exposure that is able to fully inhibit VEGFR, a protein ligand which contributes to the growth of tumors, and use in potential combinations with other targeted therapies and chemotherapy in earlier lines of treatment with larger patient populations.

Field of Use
Fruquintinib (HMPL-013), is a targeted oncology therapy for the potential treatment of various types of solid tumors.

The Field means all uses.  Initial Indications mean 3rd line colorectal cancer, 3rd line non-small cell lung cancer and 2nd line advanced gastric cancer. Each of the Initial Indications shall be an Initial Indication.

IPSCIO Record ID: 284140

License Grant
Licensor granted Licensee worldwide exclusive development and commercialization rights to capmatinib and certain back-up compounds in all indications.
License Property
Capmatinib is a potent and highly selective MET inhibitor. The investigational compound has demonstrated inhibitory activity in cell-based biochemical and functional assays that measure MET signaling and MET dependent cell proliferation, survival and migration.
c-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF). These inhibitors may have therapeutic application in the treatment of various types of cancers.
Field of Use
Capmatinib is being evaluated in patients with hepatocellular carcinoma, non-small cell lung cancer and other solid tumors, and may have potential utility as a combination agent.

IPSCIO Record ID: 256505

License Grant
The 2018 Amendment covers adjustments in the respective roles and responsibilities of the Chinese parties, in China, for the development and commercialization of fruquintinib in the areas of future life cycle planning and development, collaborations for co-development of fruquintinib with other third-party anti-cancer agents as well as promotion and distribution rights of fruquintinib.  The 2018 Amendment now gives Licensor all planning, execution and decision making responsibilities for LCI development on fruquintinib in China.  The 2018 Amendment provides Licensor the right to promote fruquintinib in provinces that represent 30% of the sales of fruquintinib in China (“Licensor Territory”) upon the occurrence of certain commercial milestones.
License Property
Fruquintinib (brand name Elunate®) is a small molecule, selective and highly potent inhibitor of VEGFR 1, 2 and 3. VEGFR inhibitors play a pivotal role in tumor-related angiogenesis, cutting off the blood supply that a tumor needs to grow rapidly.
Fruquintinib is an orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic and antineoplastic activities. Upon oral administration, fruquintinib inhibits VEGF-induced phosphorylation of VEGFRs 1, 2, and 3 which may result in the inhibition of migration, proliferation and survival of endothelial cells, microvessel formation, the inhibition of tumor cell proliferation, and tumor cell death. Expression of VEGFRs may be upregulated in a variety of tumor cell types.
Field of Use
Fruquintinib is under investigation for the treatment of NSCLC. Fruquintinib has been investigated for the treatment of ColoRectal Cancer.

IPSCIO Record ID: 329688

License Grant
Licensor, a non-profit teaching hospital, grants an exclusive license under Licensors rights in the Patent Rights to make, have made, use, have used, Sell, have Sold, import and have imported Patented Products and Patented Uses.   Licensor grants the right to  grant sublicenses.
License Property
The Patent application is entitled ALK-Fc exhibits activity in Renal cancer murine xenografts as a single agent and in combination with VEGFR inhibition.

mTOR-targeted inhibitor means a direct inhibitor of the protein called the mammalian target of rapamycin. Each of the following compounds is a non-limiting example of an mTOR-targeted inhibitor everolimus and temsirolimus.

ALKl Product means (i) anALKl (activin receptor-like kinase 1) polypeptide comprising a ligand binding portion of the extracellular domain of a vertebrate ALK 1, particularly human ALKl (e.g. a fusion protein including the ALKl ligand binding domain fused to an Fe p01iion of an IgG); (ii) an antibody that binds to the extracellular domain of human ALKl; (iii) an antibody that binds to human BMP9; or (iv) an antibody that binds to human BMPI0. For clarity, proteins that include the amino acid sequence described as SEQ ID NO 3 or SEQ ID NO5 in U.S. Patent No. 8,158,584 are included in the term ALKl Product.

RTKI means a small-molecule receptor tyrosine kinase inhibitor that binds to and inhibits signaling of VEGFRI, VEGFR2, or VEGFR3. An RTKI may, but need not, bind to and inhibit receptor tyrosine kinases in addition to a VEGFR, such as PDGFRa, PDGFRb, RET and c-Met. Likewise, an RTKI may, but need not, inhibit a different class of kinases that are not cell surface receptors, such as the serine kinases B-raf and c-raf kinase. Each of the following compounds is a non-limiting example of an RTKI sorafenib, pazopanib, axitinib, tivozanib, sunitinib, vandetanib, motesanib, vatalanib and samaxanib.

Field of Use
The Patented Use means the use of an ALKI Product and (i) an RTKI or (ii) an mTORtargeted inhibitor, for the treatment of patients with renal cell carcinoma. Patented Use shall include without limitation the sequential, overlapping or simultaneous dosing of patients with an ALKI Product and the RTKI or mTOR-targeted inhibitor. Patented Use shall also include any additional uses of ALKI Products that are the subject of a valid Claim of the Licensed Patents.

IPSCIO Record ID: 226529

License Grant
The parties agreed to collaboratively develop sitravatinib in Asia (excluding Japan and certain other countries), Australia and New Zealand (the Licensed Territory). Under this Agreement, Licensor granted Licensee an exclusive license to develop, manufacture and commercialize sitravatinib in the Licensed Territory, with Licensor retaining exclusive rights for the development, manufacturing and commercialization of sitravatinib outside the Licensed Territory.
License Property
Sitravatinib is an oral, spectrum-selective kinase inhibitor that potently inhibits specific receptor tyrosine kinases (“RTKs”). RTKs are families of kinases involved in the transmission of signals that regulate cell growth, survival, and migration and include TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET. Sitravatinib addresses cancer via two distinct mechanisms directly, by targeting RTKs that drive tumor growth through mutation, and indirectly, by modulating immune regulatory cells to stimulate the body’s immune response to tumors. Sitravatinib’s potent inhibition of TAM and split family receptors may help overcome resistance to immune checkpoint inhibitors and stimulate the body’s immune response to help detect and destroy tumor cells. Blocking the signaling of these RTKs enhances the ability of T-cells (a type of white blood cell that is of key importance to the immune system) to recognize and eliminate tumor cells and modifies the tumor immune environment to enable a more productive immune response. The ability of sitravatinib to enhance the activity of immune checkpoint inhibitors was demonstrated in nonclinical cancer models.
Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 26536

License Grant
The Licensee announced that the Licensor decided not to exercise its option under the product development and commercialization Agreement between the Licensee and the Licensor to License XL647 for further development and commercialization. The Licensee reported in May 2007 that it had notified the Licensor of it's determination that it had achieved proof-of-concept for XL647 based on data from a phase 2 clinical trial, thereby triggering a 90-day review period in which the Licensor could exercise its option. As a result of the decision by the Licensor not to exercise its option, the Licensee retains the right to develop and commercialize XL647 either independently or in collaboration with third parties.
Field of Use
The Licensee intends to move forward with the full development of XL647 in patients with non-small cell lung cancer and potentially other indications.  XL647 is a potent inhibitor of multiple RTKs implicated in driving tumor cell proliferation and tumor vascularization (blood vessel formation). XL647 inhibits the EGF, HER2, and VEGF RTKs, each of which is a target of currently approved cancer therapies. In addition, XL647 inhibits EphB4, an RTK that is highly expressed in many human tumors and plays a role in promoting angiogenesis. In a broad array of preclinical tumor models including breast, lung, colon and prostate cancer, XL647 demonstrated potent inhibition of tumor growth and causes tumor regression. In cell culture models, XL647 retains significant potency against mutant EGFRs that are resistant to current EGFR inhibitors.

IPSCIO Record ID: 369254

License Grant
Licensor grants to Licensee of the Russian Federation an exclusive right and license or  sublicense, as applicable, to the Licensed Technology to research, develop, make, have made, use, sell, offer for sale and import the Licensed Compound, Licensed Products and Licensed Product Biomarkers for the Field in the Licensee Territory.

This agreement includes a non-exclusive grant back to Licensor from Licensee.

License Property
Licensor develops, manufactures and commercializes products incorporating the proprietary compound known as tivozanib for the treatment of cancer.

Licensed Compound means the chemical compound 1-[2-chloro-4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-3-(5-methyl-1,2-oxazol-3-yl)urea, otherwise known as tivozanib, and any and all pharmaceutically acceptable, acids, bases, esters, isomers, enantiomers, salts, stereoisomers, racemates, tautomers, polymorphs, complexes, chelates, crystalline and amorphous forms, prodrugs, solvates (including hydrates), metabolites and metabolic precursors, whether active or inactive, thereof.

Licensed patents are
Neuropilin-1 as a serum based biomarker;
Quinoline Derivatives and Quinazoline Derivatives having Azolyl Group; and,
Tivozanib Response Prediction.

Licensed Know-how is module 3 of the New Drug Application for tivozanib hydrochloride for the treatment of renal cell carcinoma.  

Licensed Product Biomarker means any and all biomarkers, including metabolite, DNA, RNA and protein profiles, discovered or developed by or on behalf of Licensor or Licensee during the Term that are for use with, including use in clinical testing of or use in any decision whether to prescribe, or relate to, are associated with or are correlated with patient populations who do or do not respond to treatment with, in the case of each, any one or more Licensed Products.

Tivozanib A potent, selective, long half-life vascular endothelial growth factor (“VEGF”) tyrosine kinase inhibitor (“TKI”) of VEGF receptors 1, 2 and 3. The Licensor is evaluating several potential paths for the development of tivozanib, including a second phase 3 trial of tivozanib in refractory renal cell carcinoma, or RCC.

Field of Use
The Field means the diagnosis, prevention and treatment of any disease or condition in humans other than non-oncologic diseases or conditions of the eye.

This agreement purpose is for the development, manufacturing and commercialization of Licensors small molecule vascular endothelial growth factor (YEGF) tyrosine kinase inhibitor tivozanib in the territories of Russia, Ukraine and the Commonwealth of Independent States (CIS), for all indications excluding ocular conditions.

IPSCIO Record ID: 245935

License Grant
Licensor hereby grants to Swiss Licensee and its Affiliates an exclusive, non-transferable (except as expressly authorized in this Agreement), royalty-bearing license, with the right to sublicense as qualified, under the Licensed Patents, Licensed Products Improvements to the extent Controlled by Licensor, and Licensed Know-How to use, develop, import, offer for sale, have sold and sell, the Licensed Products in the Territory, and a non-exclusive license thereunder to make and have made the Licensed Products worldwide, for all diagnostic, preventive and therapeutic uses in the human diseases Myelodysplastic Syndromes (“MDS”) Acute Myelogenous Leukemia (“AML”) and any other indications or uses (the “Field”).  Licensor also hereby grants Licensee a license to use the Dacogen Trademark as provided in this Agreement. Licensor reserves all rights not expressly granted herein, and no other rights shall be considered granted by Licensor by implication, estoppel, reliance, or otherwise. Notwithstanding anything to the contrary, no rights or licenses are granted by Licensor in this Agreement with respect to any active ingredient other than Decitabine or with respect to any product other than the Licensed Products.
License Property
Licensed Patents
6,613,753 – Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
6,982,253 – Liquid formulation of decitabine and use of the same
6,998,391 – Method for treating diseases associated with abnormal kinase activity
6,905,669 – Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase

DACOGEN Trademark shall me mean the DACOGEN mark and accompanying logos associated with it.

Products shall mean (i) the product containing Decitabine which is the subject of Licensor’s NDA No. 21-790 as of the date of signing of this Agreement; and (ii) any other pharmaceutical product containing as an active ingredient Decitabine.

Decitabine shall mean the compound identified below, and all stereoisomers, salts and polymorphs of the compound identified below. Esters and acids of the compound identified below shall be included to the extent they constitute the same active ingredient as the compound identified below.

Decitabine
C8H12N404
Exact Mass 228.086
Mol. Wt. 228.205

Field of Use
The Field shall mean preventive and therapeutic uses in the human diseases Myelodysplastic Syndromes (“MDS”) Acute Myelogenous Leukemia (“AML”) and any other indications or uses.

Myelodysplastic syndromes (MDS) are a group of cancers in which immature blood cells in the bone marrow do not mature and therefore do not become healthy blood cells.

IPSCIO Record ID: 29334

License Grant
Parties hereto shall work together to complete the research and development of anti-tumor drug AL6802 (a chemical compound that covered by the pending U.S. patent and the future PCT patent application mentioned above) in China (and other countries and regions outside China), and finally have AL6802 Pharmaceutical registration and invention patent granted in China mainland and carry out relevant commercial development in China and other countries and regions outside China. The period for the royalties shall be the patent protection period of AL6802 in China.  Al-6802 belongs to a series of small molecules developed that have very potent activity at in vitro human cancer cell proliferation assay and in vivo human cancer cell A431 xenograft model.
Field of Use
This compound is targeting epidermal growth factor receptor (EGFR) for cancer treatment.

IPSCIO Record ID: 322039

License Grant
The parties collaborated to globally develop and commercialize Licensor’s ladiratuzumab vedotin (MK-6440). The collaboration will pursue a broad joint development program evaluating ladiratuzumab vedotin as monotherapy and in combination with Keytruda (pembrolizumab) in triple-negative breast cancer, hormone receptor-positive breast cancer and other LIV-1-expressing solid tumors.

Licensor granted Licensee an exclusive license to commercialize Tukysa (tucatinib) for the treatment of HER2-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the United States, Canada and Europe. Licensor will be responsible for marketing applications seeking approval in its territories, supported by the positive results from the HER2CLIMB clinical trial. Licensor will also co-fund a portion of the Tukysa global development plan, which encompasses several ongoing and planned trials across HER2-positive cancers, including breast, colorectal, gastric and other cancers set forth in a global product development plan.

License Property
Ladiratuzumab vedotin (MK-6440), an investigational antibody-drug conjugate targeting LIV-1, which is currently in Phase 2 clinical trials for breast cancer and other solid tumors.

Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor to treat a type of breast cancer.

HER2-positive cancers is a protein that can promote the growth of breast cancer cells. Breast cancer cells with high levels of HER2 are called HER2-positive.

Licensor is a biotechnology company that study the subtlest biological mechanisms in search of therapies that will improve the lives of those who suffer from serious diseases including cancer.

Field of Use
The field of use is for the treatment of cancer such as breast cancer.

HER2-positive breast cancer is a type of breast cancer in which breast cancer cells have a protein receptor called HER2 (human epidermal growth factor receptor 2).

Licensee is a premier research-intensive biopharmaceutical company that researches medicines and vaccines to prevent and treat diseases including cancers.

IPSCIO Record ID: 227271

License Grant
The University grants to Licensee
– the exclusive worldwide license in the Field of Use to use the Patent to manufacture and sell the Product; and,
– the right to grant sublicenses to any Patent licensed exclusively hereunder, provided that any Sublicensee agrees to be bound by the terms and conditions of this Agreement applicable to Sublicensees.

The agreement is exclusive except for the non-exclusive license granted to the U.S. government

License Property
The patents are for Method and Composition for Angiogenesis Inhibition, Generation And Use Of Mab FM155 To Inhibit Angiogenesis and Tumor Growth, and, Generation And Use Of MABXL313 To Inhibit
Angiogenesis And Tumor Growth In Vivo.

2805 60/114,878 January 6, 1999 Method and Composition for Angiogenesis Inhibition

2806 60/114,877 January 6, 1999 Method and Composition for Angiogenesis Inhibition

2908 60/143,581 July 13, 1999 Generation And Use Of Mab FM155 To Inhibit Angiogenesis and Tumor Growth

2909 60/143,534 July 13, 1999 'Generation And Use Of MAB XL313 To Inhibit Angiogenesis And Tumor Growth In Vivo

Anti-Angiogenesis for the Treatment of Cancer

In a process known as angiogenesis, cancer cells stimulate the formation of new blood vessels in order to bring oxygen and nutrients to rapidly-growing tumor tissue. The onset of angiogenesis is caused mainly by tumor cell production of growth factors that activate the cells that line the blood vessels. These activated cells begin to divide and lead to the remodeling of the extracellular matrix, which is a dense protein network that provides support and growth signals for blood vessels and tumors.

Field of Use
Field of Use shall mean any field of use.

IPSCIO Record ID: 135967

License Grant
This amendment includes commercialization rights for cabozantinib in Canada.
License Property
Cobimetinib is a potent, highly selective inhibitor of MEK, a kinase that is a component of the RAS/RAF/MEK/ERK pathway. This pathway mediates signaling downstream of growth factor receptors, and is prominently activated in a wide variety of human tumors.  It is indicated in combination with vemurafenib as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma.  The company is a biopharmaceutical company that discovers, develops and commercializes small molecule therapies for the treatment of cancer.  The business focuses predominantly on the development and commercialization of cabozantinib, an internally-discovered inhibitor of multiple receptor tyrosine kinases, in various tumor indications. Cabozantinib is currently approved in the United States and European Union for the treatment of progressive, metastatic medullary thyroid cancer, or MTC, and is marketed under the brand name COMETRIQ®.
Field of Use
The Company is developing its proprietary compound known as cabozantinib for the treatment of cancer, and owns or controls certain patents, know-how and other intellectual property relating to such compound.

IPSCIO Record ID: 367330

License Grant
Licensor hereby grants to Canadian Licensee (a) an exclusive, worldwide license under the Licensor Product-Specific Technology Patents and the Joint Patents to any Product-Specific Technology and (b) a non-exclusive, worldwide license under the Licensor Core Technology Patents, both licenses solely to develop, make, have made, use, sell, offer for sale, have sold and import Products. The licenses granted to Licensee are sublicensable only in connection with a license of Products to a Third Party for the continued development and commercialization of Products in accordance with the terms of this Agreement.
License Property
Product means a pharmaceutical preparation comprising any single antisense inhibitor generated under the Project Plan which down regulates IGFBP-5 and/or IGFBP-2. After the Project Plan has been completed, the Parties will append to this Agreement the specific sequence and chemistry of each antisense inhibitor which constitutes the active pharmaceutical ingredient in each Product.

IGFBP-5 means the gene target Insulin-like Growth Factor Binding Protein 5.

IGFBP-2 means the gene target Insulin-like Growth Factor Binding Protein 2.

Product-Specific Technology means any discovery, device, process, method of use, composition, or formulation, whether or not patented or patentable, which is made or Controlled solely by Licensor or Licensee, or jointly by Licensor and Licensee, prior to the Effective Date or during the Term of this Agreement, and which relates only to the gene targets down regulated by a Product.

The compound is the first bi-specific antisense inhibitor, a single-stranded antisense drug designed to inhibit the production of two proteins simultaneously, to enter into preclinical development. OGX-225 targets both insulin-like growth factor binding protein- 5 (IGFBP-5) and insulin-like growth factor binding protein-2 (IGFBP-2), two molecules involved in the development of metastatic disease in hormone- regulated tumors such as prostate and breast cancers. Specific financial terms of the deal were not disclosed.

Field of Use
Field of use is for cancer therapies that address treatment resistance in cancer patients.

OGX-225 could prove effective as a therapeutic to prevent progression of prostate cancer and other tumor types.

The therapies are focused on reducing the production of both insulin-like growth factor binding protein-2 (IGFBP-2) and insulin-like growth factor binding protein-5 (IGFBP-5) with a single product to enhance treatment sensitivity and delay tumor progression in patients who are resistant to hormone ablation therapy. In the treatment of tumors that require hormones for growth, clinicians use hormone ablation therapy to inhibit the production of the primary hormone (e.g. testosterone or estrogen) required for tumor growth. While tumors often regress initially following hormone ablation therapy IGFBP-2 or IGFBP-5 make available to the tumor an alternate hormone, insulin-like growth factor-1, or IGF-1, that facilitates continued tumor growth. By inhibiting the production of IGFBP-2 and IGFBP-5, the tumors access to IGF-1 is reduced and tumor growth is delayed.

IPSCIO Record ID: 243413

License Grant
Licensor grants an exclusive, worldwide license to Licensors entire interest in and to Licensed Patents within the Field to make, have made, use, import, have imported, sell, offer for sale and otherwise exploit and distribute Licensed Products, and,  practice any method, process or procedure included within the Licensed Patents; and to have any of the foregoing performed on its behalf by a third party.
License Property
The patents are for Vascular Targeting Agents and targeting vascular endothelial growth factor or VEGF.

The VTA technology is a proprietary therapeutic platform designed to specifically target tumor vasculature and subsequently destroy the tumor with various attached therapeutic agents.

Field of Use
Field shall mean vascular endothelial growth factor (VEGF), in the native, mutants and variants thereof, conjugated to cytotoxic drugs, toxins, radionuclides or photodynamic therapy agents for targeting tumors and cells expressing VEGF receptors and tumor blood vessels for therapy of cancer and blood vessel proliferative disorders, including but not limited to macular degeneration, diabetic retinopathy, and pannus formation.

IPSCIO Record ID: 263778

License Grant
This is a global collaboration covering two novel cancer programs  XL 184, a small molecule inhibitor currently in Phase III development and its associated development program; and,  XL281, a small molecule inhibitor of RAF kinase currently in Phase I development and its associated development program.

Licensor grants a co-exclusive license under the Licensors Licensed Know-How to clinically develop, make, have made, use, sell, offer for sale and import Co-Developed Products in the U.S.

Licensor grants a co-exclusive license under the Licensors Licensed Patents to clinically develop, make, have made, use, sell, offer for sale and import Co-Developed Products in the U.S.

Licensor grants an exclusive, subject to Licensors right to conduct Licensor Clinical Trials and work under the Backup Programs pursuant to this Agreement, license under the Licensor Licensed Know-How to clinically develop, make, have made, use, sell, offer for sale and import  Royalty-Bearing Products in the U.S.; and Products in the Royalty Territory.

Licensor grants an exclusive, subject to Licensors right to conduct Licensor Clinical Trials and work under the Backup Programs pursuant to this Agreement, license under the Licensor Licensed Patents to clinically develop, make, have made, use, sell, offer for sale and import  Royalty-Bearing Products in the U.S.; and Products in the Royalty Territory.

Licensor will grant a non-exclusive license to use such Licensor Marks solely in connection with the Commercialization of the Products in the Territory, the Trademark License Agreement.

License Property
Trademark is EXELIXIS®

Product means any therapeutic or prophylactic product that contains or comprises a Collaboration Compound. The Collaboration Compounds means  XL184; and  XL281.

XL184 means  the small molecule compound with Licensor identifier 02977184; the small molecule compounds listed in the Letter Agreement; any Program Backups to 02977184; and any isomer, racemate, salt, solvate, hydrate, metabolite, conjugate, ester, or prodrug of the compound.

XL281 means the small molecule compound with Licensor identifier 03832819;  the small molecule compounds listed in the Letter Agreement; any Program Backups to 03832819; and any isomer, racemate, salt, solvate, hydrate, metabolite, conjugate, ester, or prodrug of the compound.

XL184 provides a novel approach to the treatment of a variety of solid tumors where signaling through MET, VEGFR2 or RET plays an important role in dysregulated tumor growth and progression. XL184 has recently begun a Phase III clinical trials in medullary thyroid cancer, a disease in which RET mutations are found in a large proportion of patients. In addition, clinical trials to exploit the MET and VEGFR2 targeting of XL 184 are ongoing in patients with non-small cell lung cancer and glioblastoma. Preclinically, XL184 also exhibits inhibitory activity for .MET and VEGFR2 in a variety of breast, colon and brain tumor models.

XL28 l is a novel small molecule designed to selectively inhibit RAF kinase, which lies immediately downstream of RAS and is a key component of the RAS/RAF/MEK/ERK kinase signaling pathway. The RAS/RAF/MEK/ERK pathway plays a key role in the transmission of growth-promoting signals downstream of receptor tyrosine kinases. Dysregulation of this pathway plays a pivotal role in the progression of many human tumors, and inhibition of the pathway may be useful in the treatment of cancer. Phase I trials with this molecule are underway in order to select a dose and schedule for Phase II disease-directed trials.

Field of Use
The field of use is oncology in animals or humans.  XL 184 is currently in Phase III development for medullary thyroid cancer.  XL281 is currently in Phase I development for the treatment of patients with advanced solid tumor malignancies.

IPSCIO Record ID: 35129

License Grant
Licensor of Hong Kong grants to Licensee of Sweden, a co-exclusive license, with the right to sublicense  under the Licensor Technology and Licensor's interest in the Joint Technology, to Develop the Collaboration Compound and Collaboration Products in the Field in the Territory in accordance with the terms of this Agreement and an exclusive, even as to Licensor, license, with the right to sublicense, under the Licensor Technology and Licensor's interest in the Joint Technology, to Manufacture and Commercialize the Collaboration Products in the Field in the Territory.

For Licensee's Right of Reference. Licensor grants to Licensee and its Sublicensees a Right of Reference to all data included in the Regulatory Submissions and Regulatory Approvals Controlled by Licensor and its Affiliates relating to a Collaboration Compound or Collaboration Products to the extent necessary to obtain Regulatory Approval of any Collaboration Product in the Field in any country of the ROW Territory.

Each Party grants the other Party a worldwide, irrevocable, non-exclusive, perpetual, freely sublicensable right and license to exploit the Joint Technology in any manner without compensation.

License Property
Licensor owns or otherwise controls certain patents, patent applications, technology, know-how, scientific and technical information and other proprietary rights and information relating to the research, development and manufacture of the c-Met inhibitor known as HMPL-504.

The Agreement Compound means any compound with a molecular weight less than 1000 Da, other than a Collaboration Compound, that specifically targets the Collaboration Target and lacks material activity against other pharmaceutical targets (i.e. the IC50 value of such compound or product against another pharmaceutical target is more than thirty (30) times greater than the IC50 value of such compound or product against the Collaboration Target).

The Collaboration Compound means Licensor's proprietary compound designated by Licensor on the Effective Date as HMPL-504, with the generic name Volitinib, a novel targeted therapy and a highly selective inhibitor of the c-Met receptor tyrosine kinase for the treatment of cancer. Volitinib, which will imminently enter Phase I testing, has been discovered and developed in China.  Volitinib is a potent and highly selective c-Met inhibitor, which has been demonstrated to inhibit the growth of tumors in a series of pre-clinical disease models, especially for those tumors with aberrant c-Met signalling such as gene amplification or c-Met over-expression.

The key patent is Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor.

Savolitinib is a potential global first-in-class inhibitor of the mesenchymal epithelial transition factor, or c-Met, receptor tyrosine kinase, an enzyme which has been shown to function abnormally in many types of solid tumors. We developed savolitinib as a potent and highly selective oral inhibitor that was designed to address renal toxicity, the primary issue that has prevented all other selective c-Met inhibitors from gaining regulatory approval. In Phase I clinical studies, savolitinib has shown promising signs of clinical efficacy, causing tumor size reduction in patients with c-Met gene amplification in papillary renal cell carcinoma, non-small cell lung cancer, colorectal cancer and gastric cancer.

Field of Use
This agreement pertains to drugs for all diagnostic, prophylactic and therapeutic uses in the medical industry.

IPSCIO Record ID: 7426

License Grant
This in-License of RXDX-101 and RXDX-102 from the Licensor, an Italian state-owned biopharmaceutical company, grants the Licensee exclusive global rights to develop and commercialize RXDX-101 and RXDX-102.

The development rights under the License Agreement are exclusive for the term of the Agreement with respect to RXDX-101 and RXDX-102 and also, as to the Licensor, are exclusive for a five-year period with respect to any product candidate with activity against the target proteins of RXDX-101 and RXDX-102, and include the right to grant subLicenses.

License Property
RXDX-101 is a tyrosine kinase inhibitor directed to the TrkA, ROS1 and ALK proteins, which is in a Phase I/II clinical study in molecularly defined patient populations for the treatment of solid tumors.

RXDX-102 is a tyrosine kinase inhibitor directed to the Trk family tyrosine kinase receptors, TrkA, TrkB and TrkC, which is currently in preclinical development for the treatment of multiple cancers. Tyrosine kinases are enzymes that transfer phosphate groups from adenosine triphosphate (ATP) to cellular proteins and can function as an on/off switch for cellular functions, including cancer signaling.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.